Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Victor Moreno

Showing results (301-310 of 548) with videos related to

Pageof 55
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 25, 2010
Gene expression signature to improve prognosis prediction of stage II and III colorectal cancerRamon Salazar, Paul Roepman, Gabriel Capella, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 4, 2021
First-in-Human Study of PF-06647020 (Cofetuzumab Pelidotin), an Antibody-Drug Conjugate Targeting Protein Tyrosine Kinase 7, in Advanced Solid TumorsMichael L Maitland, Jasgit C Sachdev, Manish R Sharma, et al.
JTO Clinical and Research Reports|October 1, 2025
Evaluation of the Safety, Pharmacokinetics, and Antitumor Activity of Tusamitamab Ravtansine in Patients With Nonsquamous NSCLC With High or Moderate Expression of Carcinoembryonic Antigen-Related Cell Adhesion Molecule 5Anas Gazzah, Charles Ricordel, Antoine Italiano, et al.
JAMA Oncology|November 8, 2019
Safety, Tolerability, and Potential Clinical Activity of a Glucocorticoid-Induced TNF Receptor-Related Protein Agonist Alone or in Combination With Nivolumab for Patients With Advanced Solid Tumors: A Phase 1/2a Dose-Escalation and Cohort-Expansion Clinical TrialKimberley M Heinhuis, Matteo Carlino, Markus Joerger, et al.
Cancer Immunology, Immunotherapy : CII|August 6, 2024
Safety and clinical activity of JNJ-78306358, a human leukocyte antigen-G (HLA-G) x CD3 bispecific antibody, for the treatment of advanced stage solid tumorsRavit Geva, Maria Vieito, Jorge Ramon, et al.
Cancer Immunology, Immunotherapy : CII|July 3, 2021
First-in-human phase 1 study of budigalimab, an anti-PD-1 inhibitor, in patients with non-small cell lung cancer and head and neck squamous cell carcinomaAntoine Italiano, Philippe A Cassier, Chia-Chi Lin, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|December 13, 2022
Genetic Predictors for Fecal Propionate and Butyrate-Producing Microbiome Pathway Are Not Associated with Colorectal Cancer Risk: A Mendelian Randomization AnalysisYujia Lu, Yu Chen Zhao, Jenny Chang-Claude, et al.
Clinical Epigenetics|November 5, 2025
Constitutional epimutations in LTBP4, a component of the TGF-β signaling, and in BRCA1, as potential drivers of early-onset colorectal cancerMariona Terradas, Pilar Mur, Francisco D Morón-Duran, et al.
Scandinavian Journal of Work, Environment & Health|February 22, 2023
Association of occupational heat exposure and colorectal cancer in the MCC-Spain studyAlice Hinchliffe, Manolis Kogevinas, Antonio J Molina, et al.
Nature Communications|March 14, 2023
BET inhibitor trotabresib in heavily pretreated patients with solid tumors and diffuse large B-cell lymphomasVictor Moreno, Maria Vieito, Juan Manuel Sepulveda, et al.
Pageof 55

Showing results (301-310 of 548) with videos related to

Sort By:
Pageof 55
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 25, 2010
Gene expression signature to improve prognosis prediction of stage II and III colorectal cancerRamon Salazar, Paul Roepman, Gabriel Capella, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 4, 2021
First-in-Human Study of PF-06647020 (Cofetuzumab Pelidotin), an Antibody-Drug Conjugate Targeting Protein Tyrosine Kinase 7, in Advanced Solid TumorsMichael L Maitland, Jasgit C Sachdev, Manish R Sharma, et al.
JTO Clinical and Research Reports|October 1, 2025
Evaluation of the Safety, Pharmacokinetics, and Antitumor Activity of Tusamitamab Ravtansine in Patients With Nonsquamous NSCLC With High or Moderate Expression of Carcinoembryonic Antigen-Related Cell Adhesion Molecule 5Anas Gazzah, Charles Ricordel, Antoine Italiano, et al.
JAMA Oncology|November 8, 2019
Safety, Tolerability, and Potential Clinical Activity of a Glucocorticoid-Induced TNF Receptor-Related Protein Agonist Alone or in Combination With Nivolumab for Patients With Advanced Solid Tumors: A Phase 1/2a Dose-Escalation and Cohort-Expansion Clinical TrialKimberley M Heinhuis, Matteo Carlino, Markus Joerger, et al.
Cancer Immunology, Immunotherapy : CII|August 6, 2024
Safety and clinical activity of JNJ-78306358, a human leukocyte antigen-G (HLA-G) x CD3 bispecific antibody, for the treatment of advanced stage solid tumorsRavit Geva, Maria Vieito, Jorge Ramon, et al.
Cancer Immunology, Immunotherapy : CII|July 3, 2021
First-in-human phase 1 study of budigalimab, an anti-PD-1 inhibitor, in patients with non-small cell lung cancer and head and neck squamous cell carcinomaAntoine Italiano, Philippe A Cassier, Chia-Chi Lin, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|December 13, 2022
Genetic Predictors for Fecal Propionate and Butyrate-Producing Microbiome Pathway Are Not Associated with Colorectal Cancer Risk: A Mendelian Randomization AnalysisYujia Lu, Yu Chen Zhao, Jenny Chang-Claude, et al.
Clinical Epigenetics|November 5, 2025
Constitutional epimutations in LTBP4, a component of the TGF-β signaling, and in BRCA1, as potential drivers of early-onset colorectal cancerMariona Terradas, Pilar Mur, Francisco D Morón-Duran, et al.
Scandinavian Journal of Work, Environment & Health|February 22, 2023
Association of occupational heat exposure and colorectal cancer in the MCC-Spain studyAlice Hinchliffe, Manolis Kogevinas, Antonio J Molina, et al.
Nature Communications|March 14, 2023
BET inhibitor trotabresib in heavily pretreated patients with solid tumors and diffuse large B-cell lymphomasVictor Moreno, Maria Vieito, Juan Manuel Sepulveda, et al.
Pageof 55